News & Blog

Recent Posts



Study Seeking to Evaluate the Effectiveness of Cimzia in Females with Interstitial Cystitis/Bladder Pain Syndrome

Do you or someone you know who has IC and lives in, or is willing to travel to Southern California? If so, UCB Pharmaceuticals is sponsoring a study evaluating the drug certolizumab pegol (Cimzia) for improving the symptoms of patients with IC. Certolizumab pegol is an injectable anti-inflammatory medication. It has been available for use in the United States since the US Food and Drug Administration (FDA) approval for the treatment of Crohn’s disease on April 22, 2008. Certolizumab pegol (Cimzia) has subsequently been FDA approved for the treatment of rheumatoid arthritis, psoriasis, and ankylosing spondylitis. These diseases have similar characteristics to IC. This study is experimental as it will evaluate a new investigational use of certolizumab pegol (Cimzia) for the treatment of IC. Basic research has demonstrated that certolizumab pegol (Cimzia) should improve the symptoms of Interstitial Cystitis/Bladder Pain Syndrome. Click here for details: